Using gain and loss of function approaches in CD34+ cells from healthy donors and MDS cases, we demonstrate the role of this TF in promoting inefficient erythroid differentiation, indicating that DDIT3 may be a therapeutic target for patients with the disease. Here, TF is linked to myelodysplastic syndrome.